Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.

Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F.

Obes Rev. 2011 May;12(5):e32-43. doi: 10.1111/j.1467-789X.2010.00800.x. Epub 2010 Sep 6. Review.

PMID:
20880119
2.

Valproate-induced insulin resistance and obesity in children.

Verrotti A, la Torre R, Trotta D, Mohn A, Chiarelli F.

Horm Res. 2009;71(3):125-31. doi: 10.1159/000197868. Epub 2009 Feb 3. Review.

PMID:
19188736
3.

Metabolic and endocrine effects of valproic acid chronic treatment.

Belcastro V, D'Egidio C, Striano P, Verrotti A.

Epilepsy Res. 2013 Nov;107(1-2):1-8. doi: 10.1016/j.eplepsyres.2013.08.016. Epub 2013 Sep 4. Review.

PMID:
24076030
4.

Weight issues for people with epilepsy--a review.

Ben-Menachem E.

Epilepsia. 2007;48 Suppl 9:42-5. Review.

5.

Leptin and insulin homeostasis in epilepsy: relation to weight adverse conditions.

Hamed SA.

Epilepsy Res. 2007 Jun;75(1):1-9. Epub 2007 May 17. Review.

PMID:
17499974
6.

Weight change, genetics and antiepileptic drugs.

Chukwu J, Delanty N, Webb D, Cavalleri GL.

Expert Rev Clin Pharmacol. 2014 Jan;7(1):43-51. doi: 10.1586/17512433.2014.857599. Epub 2013 Dec 2. Review.

PMID:
24308788
7.

Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review.

Reynolds MF, Sisk EC, Rasgon NL.

Curr Med Chem. 2007;14(26):2799-812. Review.

PMID:
18045126
8.

On the association between valproate and polycystic ovary syndrome.

Genton P, Bauer J, Duncan S, Taylor AE, Balen AH, Eberle A, Pedersen B, Salas-Puig X, Sauer MV.

Epilepsia. 2001 Mar;42(3):295-304. Review.

9.

Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy.

Isojärvi JI, Taubøll E, Herzog AG.

CNS Drugs. 2005;19(3):207-23. Review.

PMID:
15740176
10.
11.

[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].

Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN.

Encephale. 2005 Jul-Aug;31(4 Pt 1):507-16. Review. French.

PMID:
16389718
12.

Endocrine and metabolic changes in epileptic patients receiving valproic acid.

Verrotti A, Greco R, Latini G, Chiarelli F.

J Pediatr Endocrinol Metab. 2005 May;18(5):423-30. Review.

PMID:
15921170
13.

Oral valproic acid for epilepsy--long-term experience in therapy and side effects.

Gerstner T, Bell N, König S.

Expert Opin Pharmacother. 2008 Feb;9(2):285-92. doi: 10.1517/14656566.9.2.285 . Review.

PMID:
18201150
14.

[Polycystic ovary syndrome and valproic acid].

Ribacoba Montero R, Martínez-Faedo C, Salas-Puig J.

Rev Neurol. 2003 Nov 16-30;37(10):975-82. Review. Spanish.

15.

Drug treatment of epilepsy in elderly people: focus on valproic Acid.

Stephen LJ.

Drugs Aging. 2003;20(2):141-52. Review.

PMID:
12534314
16.

Weight gain associated with use of psychotropic medications.

Sachs GS, Guille C.

J Clin Psychiatry. 1999;60 Suppl 21:16-9. Review.

17.

Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy.

Davis R, Peters DH, McTavish D.

Drugs. 1994 Feb;47(2):332-72. Review.

PMID:
7512905
18.

Valproate in the treatment of epilepsy in people with intellectual disability.

Friis ML.

J Intellect Disabil Res. 1998 Dec;42 Suppl 1:32-5. Review.

PMID:
10030429
19.

Bodyweight gain and anticonvulsants: a comparative review.

Jallon P, Picard F.

Drug Saf. 2001;24(13):969-78. Review.

PMID:
11735653
20.

Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.

Pijl H, Meinders AE.

Drug Saf. 1996 May;14(5):329-42. Review.

PMID:
8800628

Supplemental Content

Support Center